NASDAQ:KRRO Korro Bio (KRRO) Stock Price, News & Analysis → This 1 Biotech Stock has been shocking the markets (From Huge Alerts) (Ad) Free KRRO Stock Alerts $53.53 -1.35 (-2.46%) (As of 11:09 AM ET) Add Compare Share Share Today's Range$53.53▼$55.9950-Day Range$49.08▼$90.0052-Week Range$9.15▼$97.91Volume2,548 shsAverage Volume28,286 shsMarket Capitalization$429.47 millionP/E RatioN/ADividend YieldN/APrice Target$126.25 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get Korro Bio alerts: Email Address Korro Bio MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside130.0% Upside$126.25 Price TargetShort InterestBearish2.58% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingAcquiring Shares$999,992 Bought Last QuarterProj. Earnings GrowthDecreasingFrom ($10.43) to ($10.91) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.26 out of 5 starsMedical Sector733rd out of 915 stocksPharmaceutical Preparations Industry343rd out of 426 stocks 3.5 Analyst's Opinion Consensus RatingKorro Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageKorro Bio has only been the subject of 4 research reports in the past 90 days.Read more about Korro Bio's stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted2.58% of the float of Korro Bio has been sold short.Short Interest Ratio / Days to CoverKorro Bio has a short interest ratio ("days to cover") of 4.2.Change versus previous monthShort interest in Korro Bio has recently increased by 24.21%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldKorro Bio does not currently pay a dividend.Dividend GrowthKorro Bio does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for KRRO. Previous Next 0.6 News and Social Media Coverage MarketBeat Follows1 people have added Korro Bio to their MarketBeat watchlist in the last 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Korro Bio insiders have bought more of their company's stock than they have sold. Specifically, they have bought $999,992.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders16.80% of the stock of Korro Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 13.18% of the stock of Korro Bio is held by institutions.Read more about Korro Bio's insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Korro Bio are expected to decrease in the coming year, from ($10.43) to ($10.91) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Korro Bio is -0.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Korro Bio is -0.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioKorro Bio has a P/B Ratio of 2.59. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Korro Bio's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto Swap ProfitsClaim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.Secure Your Spot Now About Korro Bio Stock (NASDAQ:KRRO)Korro Bio, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). It uses its RNA editing platform, OPERA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe alcohol-associated hepatitis, and other subsets of pain. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.Read More KRRO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart KRRO Stock News HeadlinesApril 24, 2024 | insidertrades.comInsider Buying: Korro Bio, Inc. (NASDAQ:KRRO) Major Shareholder Buys 17,857 Shares of StockApril 18, 2024 | globenewswire.comKorro Announces $70 Million Private PlacementMay 10, 2024 | Huge Alerts (Ad)This 1 Biotech Stock has been shocking the marketsSave the Date: BioStem's 2024 Q1 Call Coming Up!April 1, 2024 | globenewswire.comKorro to Participate in Upcoming Investor ConferencesMarch 26, 2024 | globenewswire.comKorro Reports Full Year 2023 Financial Results and Highlights Recent ProgressFebruary 27, 2024 | globenewswire.comKorro to Present at the TD Cowen 44th Annual Health Care ConferenceFebruary 18, 2024 | seekingalpha.comKorro Bio: An Interesting Platform With A Very Long HorizonSee More Headlines Receive KRRO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Korro Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today5/10/2024Next Earnings (Estimated)5/10/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:KRRO Previous SymbolNASDAQ:KRRO CUSIPN/A CIK1703647 Webwww.frequencytx.com Phone781-315-4600FaxN/AEmployees101Year FoundedN/APrice Target and Rating Average Stock Price Target$126.25 High Stock Price Target$180.00 Low Stock Price Target$90.00 Potential Upside/Downside+135.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($94.50) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-81,170,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-106.36% Return on Assets-72.34% Debt Debt-to-Equity RatioN/A Current Ratio8.87 Quick Ratio8.87 Sales & Book Value Annual Sales$14.07 million Price / Sales30.52 Cash FlowN/A Price / Cash FlowN/A Book Value$21.19 per share Price / Book2.53Miscellaneous Outstanding Shares8,023,000Free Float6,675,000Market Cap$429.47 million OptionableNo Data Beta2.28 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Nessan Bermingham Ph.D. (Age 51)Co-Founder & Executive Chairman Comp: $202.14kMr. Ram Aiyar MBA (Age 46)Ph.D., CEO, President & Director Comp: $844.87kDr. Jean-Francois Formela M.D. (Age 67)MBA, Co-Founder & Director Comp: $8.21kMr. Vineet Agarwal M.B.A. (Age 42)Chief Financial Officer Comp: $811.77kDr. Steven L. Colletti Ph.D. (Age 58)Chief Scientific Officer Comp: $592.89kMr. Andrew Fraley Ph.D.Co-Founder & CTOMr. Josh Rosenthal Ph.D.Co-Founder & AdvisorMr. Todd Chappell (Age 51)Chief Operating Officer Ms. Shelby Walker J.D. (Age 49)Senior VP & General Counsel Mr. Ravi Ramadas Ph.D.Vice President of Business & Corporate DevelopmentMore ExecutivesKey CompetitorsHeron TherapeuticsNASDAQ:HRTXBiomea FusionNASDAQ:BMEAAnnexonNASDAQ:ANNXLexicon PharmaceuticalsNASDAQ:LXRXNeurogeneNASDAQ:NGNEView All CompetitorsInsiders & InstitutionsVenture Opportunity Fund AtlasBought 17,857 shares on 4/22/2024Total: $999,992.00 ($56.00/share)Eventide Asset Management LLCBought 546,325 shares on 2/20/2024Ownership: 73.828%72 Investment Holdings LLCBought 276,831 shares on 2/14/2024Ownership: 37.410%Monashee Investment Management LLCBought 90,805 shares on 2/12/2024Ownership: 12.271%David L LucchinoSold 1,156 sharesTotal: $43,569.64 ($37.69/share)View All Insider TransactionsView All Institutional Transactions KRRO Stock Analysis - Frequently Asked Questions Should I buy or sell Korro Bio stock right now? 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Korro Bio in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" KRRO shares. View KRRO analyst ratings or view top-rated stocks. What is Korro Bio's stock price target for 2024? 4 Wall Street research analysts have issued 12-month price objectives for Korro Bio's stock. Their KRRO share price targets range from $90.00 to $180.00. On average, they predict the company's share price to reach $126.25 in the next twelve months. This suggests a possible upside of 130.0% from the stock's current price. View analysts price targets for KRRO or view top-rated stocks among Wall Street analysts. How have KRRO shares performed in 2024? Korro Bio's stock was trading at $47.93 at the start of the year. Since then, KRRO shares have increased by 14.5% and is now trading at $54.88. View the best growth stocks for 2024 here. Are investors shorting Korro Bio? Korro Bio saw a increase in short interest in the month of April. As of April 15th, there was short interest totaling 134,400 shares, an increase of 24.2% from the March 31st total of 108,200 shares. Based on an average daily volume of 31,900 shares, the short-interest ratio is presently 4.2 days. Approximately 2.6% of the shares of the company are sold short. View Korro Bio's Short Interest. When is Korro Bio's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024. View our KRRO earnings forecast. How do I buy shares of Korro Bio? Shares of KRRO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:KRRO) was last updated on 5/10/2024 by MarketBeat.com Staff From Our Partners[Webinar] A Deep Dive into Options Volatility: Skew & Relative ValueOICThis 1 Biotech Stock has been shocking the marketsHuge AlertsForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaGold Set to EXPLODE!Gold Safe ExchangeYou need to know these two things about AI stocks ASAP…InvestorPlaceShocking: One AI startup's revenue could surge 4,735%Manward PressHe Is Giving Away BitcoinCrypto Swap Profits Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Korro Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
